PBP1710 / Prestige BioPharma - LARVOL DELTA

Anti-CTHRC1 antibody PBP1710 enhances the efficacy of cytotoxic chemotherapy by destabilizing collagen barriers in solid tumors (ESMO 2025) - "Legal entity responsible for the study The authors. Funding Has not received any funding."

Clinical • Brain Cancer • Breast Cancer • Glioblastoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • CTHRC1

Prestige Biopharma acquires Japanese patent for antibody drug 'PBP1710' [Google translation] (HIT News) - "Prestige Biopharma...announced on the 20th that it has acquired a Japanese patent for its antibody new drug 'PBP1710' for the treatment of intractable solid cancer...The company is currently in the process of applying for patents in 16 countries....With this patent acquisition, Prestige Biopharma is beginning to fully advance into the Japanese market and is also pursuing patent registration in major markets such as the United States and Europe."

Patent • Solid Tumor

Prestige Biopharma unveils pipeline lineup at Bio USA [Google translation] (HIT News) - "PBP1510 phase 1·2a, interim analysis announced this year...Prestige Biopharma Group announced on the 7th that it held a press conference at a separate booth prepared at the '2024 Bio International Convention...PBP1710, which is in the preclinical stage and is being introduced one after another in international academic journals and academic societies...CEO Koh explained that IDC441 is a new concept ADC that combines the function of suppressing tumor development by controlling the microenvironment around the tumor, unlike the existing ADC mechanism of action that is internalized from the cell surface....Koh also disclosed the clinical progress of PBP1510, a new pancreatic cancer antibody drug being developed by Prestige Biopharma. Currently, 14 patients have received the medication at the Spanish hospital, which opened first, and the US site is undergoing final preparations and is scheduled to begin administering the medication this month."

P1/2 data • Preclinical • Trial status • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Prestige Biopharma IDC consolidates 4 research organizations to 2 [Google translation] (HIT News) - "Prestige Biopharma...announced on the 16th that its subsidiary Prestige Biopharma IDC (CEO Sang-seok Ko, Innovative Discovery Center) has undergone organizational reorganization ahead of the completion of the new antibody drug research center....The company explains that the goals of the headquarters reorganization are to expand the indications for the pancreatic cancer treatment 'PBP1510 (development code name)', verify the efficacy of 'PBP1710 (development code name)', and develop new antibody treatments and transfer technology."

Clinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Prestige Biopharma acquires Korea's 1st patent for CTHRC1 neutralizing cancer antibody (Korea Biomedical Review) - "Prestige Biopharma said on Monday that it could speed up the development of solid cancer antibody therapies thanks to the recent patent acquisition for its developed technology on PBP1710, a CTHRC1 neutralizing antibody. CTHRC1 (collagen triple helix repeat containing 1) is a protein that is highly expressed in cancers such as pancreatic cancer and non-small lung cancer (NSLC)....This is the first time in Korea that CTHRC1 has been targeted and patented to treat various intractable solid cancers, the company said. Additionally, Prestige Biopharma has applied for patents in a total of 21 countries, including the U.S., Japan, Europe, and China, and is currently undergoing registration screening."

Patent • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Thoracic Cancer